ImmunityBio, Inc. (IBRX) Tops Q3 EPS by 4c

ImmunityBio, Inc. (NASDAQ: IBRX) reported Q3 EPS of ($0.07), $0.04 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $32.06 million versus the consensus estimate of $31.88 million.

For earnings history and earnings-related data on ImmunityBio, Inc. (IBRX) click here.

You May Also Be Interested In

• SpaceX Shares Indicated To Open At $155
• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• Intuitive Machines (LUNR) June 27.50 puts active, share price down 10%